Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Total Revenue	$ 31,121	$ 30,973	$ 82,947	$ 90,638
Operating expenses:
Research and development	4,042	3,643	12,618	10,408
Selling and marketing	10,955	13,088	39,240	39,508
General and administrative	8,546	6,624	24,316	20,448
Intangible asset amortization	1,274	267	3,822	800
Total operating expenses	35,187	32,736	110,264	97,568
Loss from operations	(4,066)	(1,763)	(27,317)	(6,930)
Interest expense	(55)	(58)	(175)	(596)
Other income (loss), net	(3)	1,091	627	2,385
Net loss and comprehensive loss	$ (4,124)	$ (730)	$ (26,865)	$ (5,141)
Net loss per common share, basic and diluted (in dollars per share)	$ (0.08)	$ (0.02)	$ (0.52)	$ (0.11)
Shares used to compute net loss per common share, basic and diluted (in shares)	54,858,052	48,588,296	51,632,750	45,141,502
Testing [Member]
Revenue:
Total Revenue	$ 28,270	$ 26,723	$ 70,473	$ 78,798
Operating expenses:
Cost of revenue	9,118	9,114	26,157	26,404
Product [Member]
Revenue:
Total Revenue	2,027	0	7,149	0
Operating expenses:
Cost of revenue	1,048	0	3,539	0
Biopharmaceutical [Member]
Revenue:
Total Revenue	824	2,250	5,325	7,840
Operating expenses:
Cost of revenue	204	0	572	0
Collaborative [Member]
Revenue:
Total Revenue	$ 0	$ 2,000	$ 0	$ 4,000